Abstract: The present invention provides novel antisense oligonucleotide pharmaceutical compositions having higher RNA aggregate-removing activity than conventional pharmaceutical compositions. The pharmaceutical composition of the present invention contains an oligonucleotide having any base sequence of a repeated sequence in which cytosine-adenine-guanine trinucleotides are repeated 5 to 13 times, from the 5? end to the 3? end, and the oligonucleotide has a mixmer structure containing at least two types of RNase H inactive nucleotide analogs. The present invention provides the pharmaceutical composition of the present invention used for the treatment of some symptoms of myotonic dystrophy type 1 disease.

Abstract: A cultured spherical body that is capable of easily performing quantitative analysis of a region containing brain neurons, useful as a supply source of neurons for transplantation, and can be used suitably for drug discovery screening for neurological diseases and compound evaluation systems is obtained. Provided are a cultured spherical body including a first cell layer containing neural stem cells and/or neural progenitor cells and a second cell layer containing brain neurons, wherein the first cell layer is present in the superficial portion of the cultured spherical body, and a method for producing the cultured spherical body.

Abstract: An object of the present invention is to provide a therapeutic agent for hereditary spastic paraplegia (HSP) SPG4. Specifically, the present invention relates to a composition for preventing or treating a neurodegenerative disease such as hereditary spastic paraplegia SPG4, the composition comprising, as an active ingredient, a substance that inhibits a function of miR-33a.

Abstract: A a prophylactic or therapeutic agent for RNA virus-related diseases is provided, the prophylactic or therapeutic agent containing, as an active ingredient, at least one compound selected from the group consisting of a selective estrogen receptor modulator, an anti-tuberculosis drug, a CysLT1 receptor antagonist, a peroxisome proliferator-activated receptor ? (PPAR?) agonist, an arachidonate 5-lipoxygenase (5-LOX) inhibitor, a derivative thereof, a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable solvate thereof.

Abstract: The present invention aims to provide a neuron degeneration inhibitor. The present invention relates to a neuron degeneration inhibitor comprising a compound represented by the formula (I) wherein each symbol is as defined in the description, or a salt thereof.

Abstract: The present invention provides a prophylactic and/or therapeutic agent for Alzheimer's disease containing a compound represented by the formula (I) or the formula (II) or a salt thereof.

Abstract: A prophylactic or therapeutic agent for tauopathy, containing an inhibitor of ?2? of the voltage-dependent calcium channel is provided by the present invention.

Abstract: An information processing device includes: an acquirer configured to acquire images obtained by imaging cells differentiated from pluripotent stem cells derived from a subject; and a predictor configured to input the images acquired by the acquirer to a model trained on data in which information indicating at least an intractable neurological disease is associated with an image obtained by imaging the cells of the intractable neurological disease differentiated from the pluripotent stem cells, and predict an onset of the intractable neurological disease of the subject based on output results of the model to which the images were input.

Abstract: An information processing device includes: an acquirer configured to acquire images obtained by imaging cells differentiated from pluripotent stem cells derived from a subject; and a predictor configured to input the images acquired by the acquirer to a model trained on data in which information indicating at least a neurodegenerative disease is associated with the image obtained by imaging the cells of the neurodegenerative disease differentiated from the pluripotent stem cells, and predict an onset of the neurodegenerative disease of the subject or effects of drugs on the neurodegenerative disease, based on output results of the model to which the images were input.

Abstract: A binding wire supply system for a reinforcing bar binding machine for supplying binding wire to a reinforcing bar binding machine from the outside of the reinforcing bar binding machine that binds intersections of reinforcing bars with the binding wire, wherein the binding wire supply system includes a reel mounting unit on which a binding wire supply reel, which is arranged close to the reinforcing bar binding machine and supplies the binding wire to the reinforcing bar binding machine, is mounted; a binding wire adapter for introducing the binding wire supplied from the binding wire supply reel into a binding wire accommodating magazine of the reinforcing bar binding machine; and a binding wire insertion guide into which the binding wire is inserted from the reel mounting unit to guide the binding wire to the binding wire adapter.

Abstract: An object of the present invention is to provide ASO that can effectively suppress a formation of RNA foci spontaneously occurring in neurons having SCA36 mutation, without inducing the cleavage of NOP56 pre-mRNA. The present invention provides an oligonucleotide comprising a nucleotide sequence in which one or more nucleotide sequences represented by SEQ ID NO: 2 are consecutively connected and is complementary to pre-mRNA of NOP56 gene, wherein a structure formed by the hybridization of the oligonucleotide to the pre-mRNA is resistant to RNaseH.

Abstract: An object of the present invention is to provide a therapeutic agent for hereditary spastic paraplegia (HSP) SPG4. Specifically, the present invention relates to a composition for preventing or treating a neurodegenerative disease such as hereditary spastic paraplegia SPG4, the composition comprising, as an active ingredient, a substance that inhibits a function of miR-33a.

Abstract: A self-propelled robot for rebar binding including wheel units that travel on intersecting rebars; frame units mounted multiply aligned on right and left of the wheel units corresponding to an array interval of the rebars on which the wheel unit travels, binder holding units positioned between a front wheel and rear wheel of the wheel unit and by which rebar binders that bind intersecting rebars are detachably mounted per each wheel unit; driving units each having a binder driving portion that drives the binder holding unit up and down; and a control unit that controls travel motion of the wheel units and binding motion of the rebar binder. The driving units each include a trigger driving pin, and the control unit having a binding control portion that causes the trigger driving pins of the driving units to simultaneously and respectively press the triggers of the rebar binders.

Abstract: The present invention provides a prophylactic or therapeutic agent for Alzheimer's disease (AD) containing a combination of two or more compounds selected from the group consisting of compounds shown by compound Nos. 1 to 130. Since these compounds are existing drugs that have already been confirmed actually for safety and pharmacokinetics in human, they can be a means for a pre-emptive treatment of people at risk of AD and in a stage before developing mild cognitive impairment (MCI).

Abstract: A self-propelled robot for rebar binding including wheel units that travel on intersecting rebars; frame units mounted multiply aligned on right and left of the wheel units corresponding to an array interval of the rebars on which the wheel unit travels, binder holding units positioned between a front wheel and rear wheel of the wheel unit and by which rebar binders that bind intersecting rebars are detachably mounted per each wheel unit; driving units each having a binder driving portion that drives the binder holding unit up and down; and a control unit that controls travel motion of the wheel units and binding motion of the rebar binder. The driving units each include a trigger driving pin, and the control unit having a binding control portion that causes the trigger driving pins of the driving units to simultaneously and respectively press the triggers of the rebar binders.

Abstract: The present invention provides a prophylactic and/or therapeutic agent for ALS containing a Src/c-Abl pathway inhibitor.

Abstract: A liquid injection method for injecting a liquid into a culture vessel includes tilting the culture vessel around a horizontal axis at a tilt angle (X°) of greater than 0° and 50° or less, wherein adherent cells are adhered to the culture vessel; and injecting the liquid into the culture vessel at a predetermined linear velocity (Y mm/s) via a wall surface of the culture vessel tilted at the tilt angle (X°), wherein the tilt angle (X) and the linear velocity (Y) satisfy the following (formula 1): Y?5.075X+123 (formula 1).

Abstract: An object of the present invention is to provide ASO that can effectively suppress a formation of RNA foci spontaneously occurring in neurons having SCA36 mutation, without inducing the cleavage of NOP56 pre-mRNA. The present invention provides an oligonucleotide comprising a nucleotide sequence in which one or more nucleotide sequences represented by SEQ ID NO: 2 are consecutively connected and is complementary to pre-mRNA of NOP56 gene, wherein a structure formed by the hybridization of the oligonucleotide to the pre-mRNA is resistant to RNaseH.

Abstract: The present invention provides a prophylactic and/or therapeutic agent for Alzheimer's disease containing a compound represented by the formula (I) or the formula (II) or a salt thereof.

Abstract: The present invention aims to provide a composition for the prevention or treatment of TDP-43 proteinopathy using a microRNA targeting the TDP-43 gene. A prophylactic or therapeutic composition for TDP-43 proteinopathy, comprising: one or more nucleic adds selected from the group consisting of isolated RNAs and isolated nucleic acids encoding the RNAs, wherein the RNAs consist of human miR-33 represented by SEQ ID NO: 1, variants of the human miR-33 having one or more mutations, and precursors of the human miR-33 and the variants.